Biotech Values

[DewDiligence]

EMIS off 30% as NVS dumps oral PTH program:

http://finance.yahoo.com/news/Emisphere-Receives-Notice-of-pz-1668969247.html?x=0&.v=1

Novartis informed Emisphere that, although the study confirmed that oral PTH1-34 was both safe and well-tolerated, several clinical endpoints were not met. Based on the data analyzed, Novartis has terminated the study and anticipates no further work on the oral formulation of PTH1-34.

EMIS is one of those biotech companies that never seems to get anything right. The company is still reeling from the debacle with oral insulin five years ago (#msg-14395914, #msg-14397293) and has never been adequately capitalized.